Veritable’s Petros Pharmaceuticals PTPI Stock Holding History

Veritable’s Portfolio PTPI Stock Details PTPI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-67	Closed	-$14K	–	873
2022 Q2	$14K	Buy	+67	New	+$16.8K	﹤0.01%	896

Other funds holding PTPI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Veritable's PTPI Position: Q3 2022 in Review

Veritable sold out of Petros Pharmaceuticals (PTPI) in Q3 2022, closing a stake of 67 shares — an estimated $14K sold.

Veritable first reported a position in PTPI in Q2 2022 and held it in 1 quarter. The position peaked at $14K in Q2 2022. 11 funds tracked by Wall St. Rank hold PTPI as of Q3 2022.

Veritable reported no remaining Petros Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Veritable sold 67 Petros Pharmaceuticals shares in Q3 2022, an estimated $14K.
Veritable first reported a position in Petros Pharmaceuticals in Q2 2022 and held it in 1 quarter.
Veritable's Petros Pharmaceuticals position peaked at $14K in Q2 2022.
11 funds tracked by Wall St. Rank held Petros Pharmaceuticals as of Q3 2022.

Based on Veritable's 13F filing for Q3 2022, filed 14 Nov 2022.